EA201001413A1 - Соединения и композиции в качестве модуляторов активности tlr - Google Patents
Соединения и композиции в качестве модуляторов активности tlrInfo
- Publication number
- EA201001413A1 EA201001413A1 EA201001413A EA201001413A EA201001413A1 EA 201001413 A1 EA201001413 A1 EA 201001413A1 EA 201001413 A EA201001413 A EA 201001413A EA 201001413 A EA201001413 A EA 201001413A EA 201001413 A1 EA201001413 A1 EA 201001413A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- connections
- compositions
- activity modulators
- tlr activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В заявке описан новый класс соединений, фармакологические композиции, содержащие такие соединения, и способы применения таких соединений для лечения или профилактики заболеваний или нарушений, ассоциированных с Toll-подобными рецепторами, включая TLR7 и TLR8. В первом объекте соединения пригодны для использования в качестве адьювантов для повышения эффективности вакцины (формула I), где Хобозначает N, Хобозначает N или CR, а Xобозначает -CR=CR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3313908P | 2008-03-03 | 2008-03-03 | |
US14833609P | 2009-01-29 | 2009-01-29 | |
PCT/US2009/035563 WO2009111337A1 (en) | 2008-03-03 | 2009-02-27 | Compounds and compositions as tlr activity modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201001413A1 true EA201001413A1 (ru) | 2011-04-29 |
EA018068B1 EA018068B1 (ru) | 2013-05-30 |
Family
ID=40677604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001413A EA018068B1 (ru) | 2008-03-03 | 2009-02-27 | Соединения и композиции в качестве модуляторов активности tlr |
Country Status (35)
Country | Link |
---|---|
US (2) | US8466167B2 (ru) |
EP (1) | EP2268618B1 (ru) |
JP (1) | JP5380465B2 (ru) |
KR (1) | KR101208778B1 (ru) |
CN (1) | CN102015651B (ru) |
AR (1) | AR071281A1 (ru) |
AU (1) | AU2009222105B2 (ru) |
BR (1) | BRPI0909037B8 (ru) |
CA (1) | CA2716706C (ru) |
CL (1) | CL2009000498A1 (ru) |
CO (1) | CO6321278A2 (ru) |
CR (1) | CR11682A (ru) |
CY (1) | CY1116654T1 (ru) |
DK (1) | DK2268618T3 (ru) |
EA (1) | EA018068B1 (ru) |
EC (1) | ECSP10010513A (ru) |
ES (1) | ES2546213T3 (ru) |
HK (1) | HK1152307A1 (ru) |
HR (1) | HRP20150892T1 (ru) |
HU (1) | HUE027249T2 (ru) |
IL (1) | IL207580A0 (ru) |
JO (1) | JO3065B1 (ru) |
MA (1) | MA32172B1 (ru) |
MX (1) | MX2010009738A (ru) |
MY (1) | MY150481A (ru) |
NZ (1) | NZ588191A (ru) |
PE (1) | PE20091621A1 (ru) |
PL (1) | PL2268618T3 (ru) |
PT (1) | PT2268618E (ru) |
RS (1) | RS54190B1 (ru) |
SI (1) | SI2268618T1 (ru) |
SV (1) | SV2010003657A (ru) |
TW (1) | TWI426075B (ru) |
WO (1) | WO2009111337A1 (ru) |
ZA (1) | ZA201006473B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2628074C2 (ru) * | 2011-09-30 | 2017-08-14 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | ТРИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-с]ПИРИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕЦЕПТОРА ГИСТАМИНА 4 (hH4R) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1790660T3 (da) * | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Heterolog ekspression af Neisseria-proteiner |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
US8168794B2 (en) | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
US9517263B2 (en) | 2009-06-10 | 2016-12-13 | Glaxosmithkline Biologicals Sa | Benzonaphthyridine-containing vaccines |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
EP3988115A3 (en) | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
BR112012004806B8 (pt) * | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
TW201129565A (en) | 2010-01-12 | 2011-09-01 | Hoffmann La Roche | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
EP2558069A1 (en) | 2010-04-13 | 2013-02-20 | Novartis AG | Benzonapthyridine compositions and uses thereof |
JP2013532008A (ja) | 2010-05-28 | 2013-08-15 | テトリス オンライン インコーポレイテッド | 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ |
EP2591097A1 (en) | 2010-07-06 | 2013-05-15 | Novartis AG | Norovirus derived immunogenic compositions and methods |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
EP2609931B1 (en) * | 2010-08-26 | 2020-09-16 | Toray Industries, Inc. | Immunogenic composition |
AU2011295853A1 (en) | 2010-09-01 | 2013-04-04 | Irm Llc | Adsorption of immunopotentiators to insoluble metal salts |
PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
LT2707385T (lt) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Iš anksto sulieti rsv f antigenai |
NO2686520T3 (ru) | 2011-06-06 | 2018-03-17 | ||
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
KR20140066212A (ko) | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
CN103058921A (zh) * | 2011-10-21 | 2013-04-24 | 苏州滋康医药有限公司 | 一种3-溴-6-氯吡啶-2-甲酸的合成方法 |
JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
WO2013131984A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
CA2866406A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
EP2659908A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
WO2013175388A1 (en) | 2012-05-21 | 2013-11-28 | Novartis Ag | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
JP2015524418A (ja) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのcd147 |
JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン |
CA2886938A1 (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
CA2899787A1 (en) | 2013-02-01 | 2014-08-07 | Glaxosmithkline Biologicals Sa | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
CA2902342C (en) * | 2013-02-25 | 2017-10-17 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
JP6079431B2 (ja) * | 2013-05-20 | 2017-02-15 | 住友化学株式会社 | ホウ素化合物の製造方法 |
SG11201509998WA (en) | 2013-06-13 | 2016-01-28 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
EA036162B1 (ru) * | 2013-07-30 | 2020-10-08 | Янссен Сайенсиз Айрлэнд Юси | Производные тиено[3,2-d]пиримидинов для лечения вирусных инфекций |
BE1022744B1 (fr) | 2014-03-26 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Antigenes staphylococciques mutants |
ES2804101T3 (es) | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
WO2016022700A2 (en) * | 2014-08-06 | 2016-02-11 | The Scripps Research Institute | Tlr-independent small molecule adjuvants |
WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
TW201630606A (zh) * | 2015-01-21 | 2016-09-01 | 諾華公司 | 包含局部藥物之蓋崙(galenic)調配物 |
WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
HUE042563T2 (hu) | 2015-03-06 | 2019-07-29 | Hoffmann La Roche | Benzazepin-dikarboxamid vegyületek |
DK3277270T3 (da) | 2015-04-01 | 2021-12-06 | Akebia Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af anæmi |
CA2986494A1 (en) | 2015-06-03 | 2016-12-08 | Affiris Ag | Il-23-p19 vaccines |
US20180186896A1 (en) | 2015-07-07 | 2018-07-05 | Affiris Ag | Vaccines for the treatment and prevention of ige mediated diseases |
TW201717968A (zh) * | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導rig-i和其他模式辨識受體之化合物及組成物 |
EP3350168B1 (en) | 2015-09-17 | 2019-12-18 | H. Hoffnabb-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
CN105311032B (zh) * | 2015-11-09 | 2018-09-25 | 深圳大学 | Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用 |
BR112018068681A2 (pt) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas |
EP3464245B1 (en) | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with tertiary amide function |
WO2017202703A1 (en) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
EP4063358B1 (en) | 2016-12-22 | 2024-05-22 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
CN111315413A (zh) | 2017-11-07 | 2020-06-19 | 秀比特生物技术公司 | 通过IgE类特异性免疫反应的抑制效果阻止婴儿期变态反应素质获得的方法 |
CN108033918B (zh) * | 2017-12-28 | 2020-12-25 | 西安欧得光电材料有限公司 | 一种光电材料中间体2-氯-4-苯基苯并[h]喹唑啉的合成方法 |
CN112088155A (zh) | 2018-05-09 | 2020-12-15 | 阿克比治疗有限公司 | 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法 |
BR112020026890A2 (pt) | 2018-07-03 | 2021-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo |
CN112805283B (zh) * | 2018-09-19 | 2022-09-20 | 正大天晴药业集团股份有限公司 | Tlr8激动剂 |
WO2020064792A1 (en) * | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Heterocyclyl compounds for the treatment of autoimmune disease |
CN109651146A (zh) * | 2019-01-28 | 2019-04-19 | 荆楚理工学院 | 一种3-甲基-4-甲醛肟基苯甲酸乙酯的制备方法和应用 |
CN109912414B (zh) * | 2019-04-11 | 2021-09-17 | 荆门医药工业技术研究院 | 一种4-甲醛肟基苯甲酸乙酯的制备方法和应用 |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
CN112778372A (zh) * | 2019-11-11 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用 |
CA3163386A1 (en) | 2020-01-02 | 2021-07-08 | Qi Wu | Crystal form of pyridopyrimidine derivative and preparation method thereof |
WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
CN112852698B (zh) * | 2021-01-30 | 2022-11-29 | 军事科学院军事医学研究院军事兽医研究所 | 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用 |
KR20230145107A (ko) * | 2021-02-09 | 2023-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
CN116262750A (zh) * | 2021-12-15 | 2023-06-16 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法和用途 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
SU1766918A1 (ru) | 1990-04-24 | 1992-10-07 | Институт химии Башкирского научного центра Уральского отделения АН СССР | Способ получени алкил(арил)производных 5,6-бензо-1,7-нафтиридина |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
HU222247B1 (hu) * | 1991-03-01 | 2003-05-28 | Minnesota Mining And Manufacturing Company | 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható 1H-imidazo[4,5-c]kinolin-5N-oxid-származékok |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
WO1997037026A1 (en) | 1996-04-02 | 1997-10-09 | Smithkline Beecham Corporation | Novel compounds |
EP0934336A1 (en) | 1996-05-14 | 1999-08-11 | Smithkline Beecham Corporation | Novel compounds |
WO1998018931A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
DK0991761T3 (da) | 1997-08-21 | 2008-05-19 | Nederlanden Staat | Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner |
CA2671261A1 (en) | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
CA2310217A1 (en) | 1997-11-26 | 1999-06-03 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
ATE446368T1 (de) | 1998-01-14 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
WO1999053940A1 (en) | 1998-04-23 | 1999-10-28 | Uab Research Foundation | PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR |
EP2261355A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
WO2000006738A2 (en) | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
JP2002531055A (ja) | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
WO2000012689A1 (en) | 1998-08-31 | 2000-03-09 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
ATE422368T1 (de) | 1998-08-31 | 2009-02-15 | Inhibitex Inc | Multikomponenten impfstoffe gegen staphylococcus aureus |
JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
EP2050464B1 (en) | 1998-12-21 | 2019-08-07 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
JP4785014B2 (ja) | 1999-03-26 | 2011-10-05 | プロヴァリス・ユーケー・リミテッド | 蛋白質 |
ATE325620T1 (de) | 1999-06-10 | 2006-06-15 | Medimmune Inc | Streptococcus pneumoniae proteine und impfstoffe |
US6756382B2 (en) | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
ES2507100T3 (es) | 2000-01-17 | 2014-10-14 | Novartis Vaccines And Diagnostics S.R.L. | Vacuna OMV suplementada contra meningococo |
DK1790660T3 (da) | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Heterolog ekspression af Neisseria-proteiner |
CA2404260A1 (en) | 2000-03-21 | 2001-09-27 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
AU2001255772B2 (en) | 2000-04-27 | 2006-06-29 | Medimmune, Llc | Immunogenic pneumococcal protein and vaccine compositions thereof |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
WO2002008426A2 (en) | 2000-07-20 | 2002-01-31 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumoniae |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
EP1330473A2 (en) | 2000-10-26 | 2003-07-30 | Imperial College Innovations Limited | Streptococcal genes |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
AR035967A1 (es) | 2001-05-18 | 2004-07-28 | Altana Pharma Ag | Un compuesto de piridilmetilaminopirimidina, un medicamento que lo comprende y el uso del mismo |
EP2339344A1 (en) | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
CA2808598A1 (en) | 2001-08-02 | 2003-02-13 | University Of Sheffield | Antigenic polypeptides |
DK1719511T3 (da) * | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf |
EP2275122A3 (en) | 2002-04-02 | 2011-05-18 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CN100360558C (zh) | 2002-06-11 | 2008-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
PL399492A1 (pl) | 2002-08-02 | 2012-11-19 | Glaxosmithkline Biologicals S.A. | Szczepionka |
EP1551357B1 (en) | 2002-09-13 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Group b streptococcus vaccine |
JP4697706B2 (ja) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
WO2004092209A2 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
CA2526106A1 (en) | 2003-06-26 | 2005-01-13 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
CA2532369C (en) | 2003-07-31 | 2016-07-26 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
AU2005214061B2 (en) | 2004-02-18 | 2010-02-04 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
WO2006009832A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
EP1784180A4 (en) | 2004-09-02 | 2009-07-22 | 3M Innovative Properties Co | 2-AMINO-1H-IMIDAZO RING SYSTEMS AND METHOD |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
RU2415857C2 (ru) * | 2004-09-14 | 2011-04-10 | Новартис Вэксинс Энд Диагностикс Инк. | Имидазохинолиновые соединения |
EP1804833A2 (en) | 2004-09-22 | 2007-07-11 | GlaxoSmithKline Biologicals SA | Staphylococcal immunogenic compositions |
US9034345B2 (en) | 2005-01-27 | 2015-05-19 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
WO2006091394A2 (en) | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
CA2598656A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
JP2008531568A (ja) | 2005-02-23 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | ヒドロキシアルキルで置換されたイミダゾナフチリジン |
EP1851224A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
AU2006232294A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
EP1922317A4 (en) | 2005-09-09 | 2009-04-15 | Coley Pharm Group Inc | N- {2-Ý4-AMINO-2- (ETHOXYMETHYL) -1H-IMIDAZOÝ4,5-CQUINOLIN-1-YL-1,1-DIMETHYLTHYL} METHANESULFONAMIDE AMIDE AND CARBAMATE DERIVATIVES AND RELATED METHODS |
EP1977009B1 (en) | 2005-12-27 | 2016-08-17 | Obetech, LLC | Adipogenic adenoviruses as a biomarker for disease |
EP2368570A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
CA2642721A1 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
WO2007109813A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
JP5306194B2 (ja) | 2006-06-22 | 2013-10-02 | アナディス ファーマシューティカルズ インク | ピロ[1,2−b]ピリダジノン化合物 |
US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
PL2155743T3 (pl) * | 2007-05-08 | 2013-01-31 | Astrazeneca Ab | Imidazochinoliny o właściwościach immunomodulacyjnych |
CN102036561A (zh) | 2008-02-29 | 2011-04-27 | 赛林药物股份有限公司 | 蛋白激酶调节剂 |
EP2324029A4 (en) | 2008-09-10 | 2011-09-14 | Kalypsys Inc | HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT |
-
2009
- 2009-02-27 CA CA2716706A patent/CA2716706C/en active Active
- 2009-02-27 KR KR1020107022041A patent/KR101208778B1/ko active IP Right Grant
- 2009-02-27 EA EA201001413A patent/EA018068B1/ru not_active IP Right Cessation
- 2009-02-27 US US12/921,129 patent/US8466167B2/en active Active
- 2009-02-27 AU AU2009222105A patent/AU2009222105B2/en active Active
- 2009-02-27 SI SI200931254T patent/SI2268618T1/sl unknown
- 2009-02-27 NZ NZ588191A patent/NZ588191A/en unknown
- 2009-02-27 BR BRPI0909037A patent/BRPI0909037B8/pt active IP Right Grant
- 2009-02-27 PL PL09718298T patent/PL2268618T3/pl unknown
- 2009-02-27 MX MX2010009738A patent/MX2010009738A/es active IP Right Grant
- 2009-02-27 RS RS20150556A patent/RS54190B1/en unknown
- 2009-02-27 PT PT97182984T patent/PT2268618E/pt unknown
- 2009-02-27 EP EP09718298.4A patent/EP2268618B1/en active Active
- 2009-02-27 HU HUE09718298A patent/HUE027249T2/en unknown
- 2009-02-27 WO PCT/US2009/035563 patent/WO2009111337A1/en active Application Filing
- 2009-02-27 CN CN200980115846.7A patent/CN102015651B/zh active Active
- 2009-02-27 ES ES09718298T patent/ES2546213T3/es active Active
- 2009-02-27 DK DK09718298.4T patent/DK2268618T3/en active
- 2009-02-27 MY MYPI20103829 patent/MY150481A/en unknown
- 2009-02-27 JP JP2010549768A patent/JP5380465B2/ja active Active
- 2009-03-03 TW TW098106857A patent/TWI426075B/zh active
- 2009-03-03 AR ARP090100743A patent/AR071281A1/es active IP Right Grant
- 2009-03-03 CL CL2009000498A patent/CL2009000498A1/es unknown
- 2009-03-03 JO JOP/2009/0087A patent/JO3065B1/ar active
- 2009-03-03 PE PE2009000322A patent/PE20091621A1/es active IP Right Grant
-
2010
- 2010-08-12 IL IL207580A patent/IL207580A0/en active IP Right Grant
- 2010-09-03 SV SV2010003657A patent/SV2010003657A/es unknown
- 2010-09-09 ZA ZA2010/06473A patent/ZA201006473B/en unknown
- 2010-09-21 CR CR11682A patent/CR11682A/es unknown
- 2010-09-29 MA MA33208A patent/MA32172B1/fr unknown
- 2010-10-01 EC EC2010010513A patent/ECSP10010513A/es unknown
- 2010-10-04 CO CO10122816A patent/CO6321278A2/es active IP Right Grant
-
2011
- 2011-06-22 HK HK11106451.6A patent/HK1152307A1/xx unknown
-
2013
- 2013-04-22 US US13/867,752 patent/US8895577B2/en active Active
-
2015
- 2015-08-21 HR HRP20150892TT patent/HRP20150892T1/hr unknown
- 2015-08-26 CY CY20151100753T patent/CY1116654T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2628074C2 (ru) * | 2011-09-30 | 2017-08-14 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | ТРИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-с]ПИРИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕЦЕПТОРА ГИСТАМИНА 4 (hH4R) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201001413A1 (ru) | Соединения и композиции в качестве модуляторов активности tlr | |
EA201200406A1 (ru) | Соединения и композиции, которые являются модуляторами активности tlr | |
EA201270356A1 (ru) | Иммуногенные композиции, содержащие модуляторы активности tlr | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
EA201170922A1 (ru) | Производные сульфонамида | |
EA201190021A1 (ru) | Модуляторы toll-подобных рецепторов | |
EA201291073A1 (ru) | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 | |
EA201590358A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
EA201290882A1 (ru) | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
EA201492166A1 (ru) | N-замещенные бензамиды и их применение в лечении боли | |
EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
EA200970173A1 (ru) | Химические соединения | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
EA201391532A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
EA201390422A1 (ru) | Бупренорфиновые аналоги | |
EA201290121A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
ATE502633T1 (de) | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen | |
EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
EA200870360A1 (ru) | Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
EA201590697A1 (ru) | Производные кетамина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
PC4A | Registration of transfer of a eurasian patent by assignment |